Abstract
1. The response to romazarit, a disease modifying anti-rheumatoid agent, was observed in patients with rheumatoid arthritis (RA) in a double-blind placebo controlled study. 2. Two hundred and twenty-four patients were recruited from 11 centres and treated with placebo or romazarit at a dose of 200 mg or 450 mg every 12 h for up to 24 weeks. Disease activity was measured using the Ritchie Index (RI). Plasma concentrations of romazarit were measured at each of up to eight assessments of RI. 3. The effect of romazarit was examined using analysis of variance (ANOVA) in 164 patients who contributed 61% of observations of disease activity. Observations after 12 weeks of treatment were excluded from ANOVA. 4. A population pharmacokinetic-dynamic model for the time course of disease progress and the response to placebo and romazarit was used to describe observations from all patients. 5. The population model suggested that the effect of romazarit was on the rate of progress of the disease and was describable by an Emax model. Concentration was a better predictor of response than dose. 6. Romazarit was significantly better than placebo in improving the RI in patients with RA. The placebo efficacy of romazarit treatment was similar to that associated with placebo treatment. 7. The population model provided a more complete description and explanation of the clinical pharmacology and therapeutic potential of romazarit than ANOVA.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
- Bloxham D. P., Bradshaw D., Cashin C. H., Dodge B. B., Lewis E. J., Westmacott D., Self C. R. Biologic properties of romazarit (Ro 31-3948), a potential disease-modifying antirheumatic drug. J Pharmacol Exp Ther. 1990 Mar;252(3):1331–1340. [PubMed] [Google Scholar]
- Holford N. H., Peace K. E. Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11466–11470. doi: 10.1073/pnas.89.23.11466. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Holford N. H., Peace K. E. Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11471–11475. doi: 10.1073/pnas.89.23.11471. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Holford N. H., Sheiner L. B. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981 Nov-Dec;6(6):429–453. doi: 10.2165/00003088-198106060-00002. [DOI] [PubMed] [Google Scholar]
- Ritchie D. M., Boyle J. A., McInnes J. M., Jasani M. K., Dalakos T. G., Grieveson P., Buchanan W. W. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968 Jul;37(147):393–406. [PubMed] [Google Scholar]
- Williams P. E., Bird H. A., Minty S., Helliwell P. S., Muirhead G. J., Bentley J., York A. A pharmacokinetic and tolerance study of romazarit in patients with rheumatoid arthritis. Biopharm Drug Dispos. 1992 Mar;13(2):119–129. doi: 10.1002/bdd.2510130206. [DOI] [PubMed] [Google Scholar]
- Williams P. E., Muirhead G. J., Worth E., Zimmer R., Lücker P. Pharmacokinetics and tolerance of romazarit after oral administration of ascending single doses to healthy human volunteers. Eur J Drug Metab Pharmacokinet. 1990 Oct-Dec;15(4):317–322. doi: 10.1007/BF03190221. [DOI] [PubMed] [Google Scholar]